218 related articles for article (PubMed ID: 28853217)
1. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Wildeman MA; Novalic Z; Verkuijlen SA; Juwana H; Huitema AD; Tan IB; Middeldorp JM; de Boer JP; Greijer AE
Clin Cancer Res; 2012 Sep; 18(18):5061-70. PubMed ID: 22761471
[TBL] [Abstract][Full Text] [Related]
3. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
6. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
7. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
10. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
11. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
12. EBV reactivation as a target of luteolin to repress NPC tumorigenesis.
Wu CC; Fang CY; Hsu HY; Chuang HY; Cheng YJ; Chen YJ; Chou SP; Huang SY; Lin SF; Chang Y; Tsai CH; Chen JY
Oncotarget; 2016 Apr; 7(14):18999-9017. PubMed ID: 26967558
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Stoker SD; Novalić Z; Wildeman MA; Huitema AD; Verkuijlen SA; Juwana H; Greijer AE; Tan IB; Middeldorp JM; de Boer JP
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1845-57. PubMed ID: 25920375
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation.
Yip YL; Lin W; Deng W; Jia L; Lo KW; Busson P; Vérillaud B; Liu X; Tsang CM; Lung ML; Tsao SW
Lab Invest; 2018 Aug; 98(8):1093-1104. PubMed ID: 29769697
[TBL] [Abstract][Full Text] [Related]
15. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
16. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
17. Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas.
Ramayanti O; Brinkkemper M; Verkuijlen SAWM; Ritmaleni L; Go ML; Middeldorp JM
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565326
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma.
Shi F; Shang L; Zhou M; Lv C; Li Y; Luo C; Liu N; Lu J; Tang M; Luo X; Xu J; Fan J; Zhou J; Gao Q; Wu W; Jia W; Wang H; Cao Y
J Med Virol; 2024 May; 96(5):e29634. PubMed ID: 38682578
[TBL] [Abstract][Full Text] [Related]
19. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
20. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
